Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Liabilities and Shareholders Equity: 2013-2025

Historic Liabilities and Shareholders Equity for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $1.7 billion.

  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity rose 7.83% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 5.90%. This contributed to the annual value of $1.6 billion for FY2024, which is 4.27% up from last year.
  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.7 billion in Q3 2025, which was up 3.15% from $1.6 billion recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.7 billion during Q3 2025, with a 5-year trough of $645.7 million in Q1 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $1.5 billion in 2024 and averaged $1.5 billion.
  • Data for Amphastar Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 112.56% (in 2023) over the last 5 years.
  • Amphastar Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $671.5 million in 2021, then rose by 10.49% to $742.0 million in 2022, then soared by 103.90% to $1.5 billion in 2023, then increased by 4.27% to $1.6 billion in 2024, then increased by 7.83% to $1.7 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.7 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.6 billion for Q1 2025.